TRDA Stock Analysis: Buy, Sell, or Hold?
TRDA - Entrada Therapeutics, Inc. Common Stock
$7.57
-0.03 (-0.39%)
▼
5d:
+1.47%
30d:
+25.12%
90d:
+19.97%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 05, 2026
0d
Get Alerted When TRDA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: TRDA shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: TRDA shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: TRDA is currently trading at $7.57, which is considered extended relative to its 30-day fair value range of $6.35 to $7.45.
Technical Outlook: Technically, TRDA is in a strong downtrend. The price is approaching resistance at $7.79. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: TRDA scores 13/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $19.00 (+150.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, TRDA is in a strong downtrend. The price is approaching resistance at $7.79. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: TRDA scores 13/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $19.00 (+150.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$6.35 -
$7.45
Company Quality Score
28/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
26.3%
All Signals
- BEARISH: Price extended above range
- BEARISH: Weak technical setup (13/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 150.0% below Wall St target ($19.00)
- WARNING: Composite score 28/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$6.35 -
$7.45
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$6.83
Resistance Level
$7.79
Current Trend
Strong Downtrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.42
Wall Street Target
$19.00
(+150.0%)
Revenue Growth (YoY)
-53.9%
Share & Embed Analysis
Last updated: August 23, 2026 5:46 PM ET
Data refreshes hourly during market hours. Next update: 6:46 PM
Data refreshes hourly during market hours. Next update: 6:46 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is TRDA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
6
Sells
Net
INSIDERS SELLING
Recent Transactions
Kory James Wentworth
SELL
2500 shares
2026-04-01
Kory James Wentworth
SELL
11388 shares
2026-03-10
Nathan J Dowden
SELL
11894 shares
2026-03-10
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$370 | 42 HOLD |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$55 | 57 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 50 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$9 | 53 HOLD |
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$88 | 40 SELL |